Northstrive Biosciences Inc., a subsidiary of PMGC Holdings Inc., announced on June 17, 2025, the initiation of Phase II of its AI Development Program with strategic partner Yuva Biosciences, Inc. This phase focuses on leveraging AI for therapeutic development.
As part of Phase II, both companies will collaborate to use MitoNova™, YuvaBio’s AI mitochondrial science-focused artificial intelligence platform. The goal is to compile a selection of small molecule candidates that promote mitochondrial health in obesity and cardiac diseases.
YuvaBio will virtually screen a large-scale library of diverse, drug-like small molecules to predict candidates most likely to promote mitochondrial health. This will lead to an initial list of synthetic compounds for muscle preservation and metabolic health, ready for biological validation.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.